share_log

Further Weakness as Hainan Haiyao (SZSE:000566) Drops 6.7% This Week, Taking Five-year Losses to 26%

Further Weakness as Hainan Haiyao (SZSE:000566) Drops 6.7% This Week, Taking Five-year Losses to 26%

海南海藥(SZSE:000566)本週下跌6.7%,進一步走弱,五年虧損達26%。
Simply Wall St ·  01/07 13:00

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But even the best stock picker will only win with some selections. At this point some shareholders may be questioning their investment in Hainan Haiyao Co., Ltd. (SZSE:000566), since the last five years saw the share price fall 26%. Even worse, it's down 21% in about a month, which isn't fun at all. We do note, however, that the broader market is down 9.1% in that period, and this may have weighed on the share price.

爲了證明選擇個別股票的努力是合理的,值得努力超越市場指數基金的回報。但即使是最好的股票選擇者,也只會在某些選擇中獲勝。在這一點上,一些股東可能正在質疑他們對海南海藥股份有限公司(SZSE:000566)的投資,因爲過去五年股價下跌了26%。更糟糕的是,約一個月內股價下跌了21%,這一點可不令人愉快。然而,我們注意到,在此期間,整體市場下跌了9.1%,這可能對股價造成了一定壓力。

After losing 6.7% this past week, it's worth investigating the company's fundamentals to see what we can infer from past performance.

在過去一週下跌了6.7%之後,值得調查公司的基本面,以便從過去的表現中推斷出我們能得到什麼。

Given that Hainan Haiyao didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

鑑於海南海藥在過去十二個月沒有盈利,我們將關注營業收入的增長,以快速了解其業務發展。一般而言,沒有利潤的公司預計每年都要增長營業收入,並且增長幅度較大。這是因爲快速的營業收入增長可以輕鬆推斷出利潤預期,通常相當可觀。

In the last five years Hainan Haiyao saw its revenue shrink by 13% per year. That's definitely a weaker result than most pre-profit companies report. It seems pretty reasonable to us that the share price dipped 5% per year in that time. This loss means the stock shareholders are probably pretty annoyed. It is possible for businesses to bounce back but as Buffett says, 'turnarounds seldom turn'.

在過去五年中,海南海藥的營業收入每年縮減13%。這個結果明顯弱於大多數未盈利公司的報告。我們認爲,在那段時間,股價每年下降5%是相當合理的。這種損失意味着股票股東可能相當惱火。企業確實有可能復甦,但正如巴菲特所說,『翻身的事情很少發生』。

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

您可以在下面看到盈利和營業收入隨時間的變化(通過點擊圖片發現確切值)。

big
SZSE:000566 Earnings and Revenue Growth January 7th 2025
SZSE:000566 收益和營業收入增長 2025年1月7日

Take a more thorough look at Hainan Haiyao's financial health with this free report on its balance sheet.

通過這份關於海南海藥資產負債表的免費報告,更全面地了解海南海藥的財務健康狀況。

A Different Perspective

不同的視角

Hainan Haiyao provided a TSR of 3.6% over the last twelve months. Unfortunately this falls short of the market return. But at least that's still a gain! Over five years the TSR has been a reduction of 5% per year, over five years. It could well be that the business is stabilizing. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For example, we've discovered 1 warning sign for Hainan Haiyao that you should be aware of before investing here.

海南海藥在過去十二個月提供了3.6%的總回報率。 不幸的是,這低於市場回報。 但至少這依然是一個收益!在五年內,年度總回報率下降了5%。它可能確實表明業務正在穩定。 雖然考慮市場條件對股價的不同影響非常重要,但還有其他更重要的因素。例如,我們發現海南海藥有一個警告信號,在投資之前你應該注意。

But note: Hainan Haiyao may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

但請注意:海南海藥可能不是最好的買入股票。因此,請查看這份關於過去盈利增長(以及進一步增長預測)有趣公司的免費清單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文中引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall ST的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall ST在提到的任何股票中均沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論